Puma Biotechnology (PBYI) Accumulated Expenses (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Accumulated Expenses data on file, last reported at $5.4 million in Q1 2026.

• Quarterly Accumulated Expenses fell 80.06% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 80.06% YoY) and the FY2025 annual result came in at $50.0 million, up 35.59% from the prior year.
• Accumulated Expenses declined to $5.4 million in Q1 2026, from $50.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $53.0 million in Q4 2022 to a low of $590000.0 in Q3 2025.
• A 5-year average of $23.1 million and a median of $26.9 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 5721.51% — and 2025, when it sank 98.84%.
• Tracing PBYI's Accumulated Expenses over 5 years: stood at $53.0 million in 2022, then tumbled by 88.88% to $5.9 million in 2023, then soared by 525.39% to $36.9 million in 2024, then jumped by 35.59% to $50.0 million in 2025, then sank by 89.29% to $5.4 million in 2026.
• The last three Accumulated Expenses figures came in at $5.4 million (Q1 2026), $50.0 million (Q4 2025), and $590000.0 (Q3 2025), per Business Quant data.